Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Common Gastrointestinal Side Effects Gastrointestinal symptoms represent the most frequent adverse events with Retatrutide, consistent with other GLP 1 class medications
For weight management, NICE has approved liraglutide 3 mg (Saxenda) and semaglutide 2.4 mg (Wegovy) under specific criteria, including BMI thresholds and provision through specialist weight management services
Injectable and oral options
Budget realistically for a full year rather than a first month
Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines
US$ 25.34
US$ 26.24
US$ 25.00
US$ 28.81
